

## Scheme of Arrangement – Court Approval

- The Second Court Hearing took place on 13 September 2022 and 14 September 2022
- The Supreme Court of New South Wales has approved the Scheme
- It is expected that a copy of the Court’s orders will be lodged with ASIC on 15 September 2022, at which time the Scheme will be legally effective
- It is expected that ResApp’s shares will be suspended from trading on the ASX at the close of trade 15 September 2022

**Brisbane, Australia, 14 September 2022** – ResApp Health Limited (ASX:RAP) (**ResApp**) advises that the Supreme Court of New South Wales (**Court**) has today made orders approving the scheme of arrangement under which Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) (**Pfizer**) will acquire 100% of the shares in ResApp (**Scheme**).

The Second Court Hearing took place on 13 September 2022 and 14 September 2022, with an additional sitting day being required to allow the Court to consider all evidence tendered.

### Lodgement of Court Orders and Suspension of Trading

Pursuant to section 411(10) of the *Corporations Act* 2001 (Cth), the Scheme will become legally effective upon lodgement of the Court orders with the Australian Securities and Investments Commission (**ASIC**).

It is expected that a copy of the Court’s orders will be lodged with ASIC tomorrow, at which time the Scheme will become legally effective. If this occurs, ResApp’s shares will be suspended from trading on the ASX at the close of trade tomorrow, 15 September 2022.

### Important Dates and Times

The key dates expected for the Scheme are set out below:

Event	Expected Date
Effective Date of the Scheme	15 September 2022
Last day of trading of ResApp shares on ASX	15 September 2022
Record Date for determining entitlements to the Scheme Consideration	7:00pm (AEST) on 19 September 2022



Implementation Date for the Scheme and payment of 26 September 2022

Scheme Consideration

**Note:** Any changes to the above timetable will be announced to ASX and will be available under ResApp's profile on ASX at [www.asx.com.au](http://www.asx.com.au).

ResApp will update ResApp shareholders as to any material developments in relation to the Scheme as the timetable progresses.

###

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### **Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the Managing Director of ResApp Health.*